B. Riley Wealth Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

B. Riley Wealth Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$11.4K	Buy	+13,745	New	+$23.8K	﹤0.01%	714

Other funds holding SRNE

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

B. Riley Wealth Management's SRNE Position: Q2 2022 in Review

B. Riley Wealth Management opened a new position in Sorrento Therapeutics, Inc. (SRNE) in Q2 2022: 13,745 shares worth $11.4K. The stake represents ﹤0.01% of the portfolio and ranks #714 among its holdings.

229 funds tracked by Wall St. Rank hold SRNE as of Q2 2022.

B. Riley Wealth Management held 13,745 shares of Sorrento Therapeutics, Inc. worth $11.4K as of Q2 2022.
Sorrento Therapeutics, Inc. was a new B. Riley Wealth Management position in Q2 2022.
Sorrento Therapeutics, Inc. made up ﹤0.01% of B. Riley Wealth Management's portfolio in Q2 2022, its #714 holding.
229 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2022.

Based on B. Riley Wealth Management's 13F filing for Q2 2022, filed 9 Sep 2022.